WEBULL
WebtradeDownload

The Bull Case For Axsome Therapeutics (AXSM) Could Change Following AXS-05 Phase 3 Smoking Trial Launch

Simply Wall St · 1d ago
  • Axsome Therapeutics recently announced that the first patient has been dosed in the SUMMIT Phase 3 smoking cessation trial of AXS-05, a randomized, double-blind, active- and placebo-controlled study comparing AXS-05, bupropion, and placebo over 12 weeks with smoking abstinence as the primary endpoint.
  • This milestone not only aims to extend AXS-05’s use beyond its existing approvals in major depressive disorder and Alzheimer’s-related agitation, but also seeks to open a new indication protected by patents out to at least 2043.
  • We’ll now examine how initiating the SUMMIT Phase 3 smoking cessation trial could reshape Axsome’s investment narrative and long-term CNS portfolio outlook.

AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Axsome Therapeutics Investment Narrative Recap

To own Axsome, you need to believe its growing CNS portfolio can eventually offset current net losses and heavy commercial spend, while key late stage programs de risk the story. The SUMMIT Phase 3 start in smoking cessation modestly broadens the AXS 05 opportunity, but it does not change that near term, execution on Auvelity, Sunosi and SYMBRAVO uptake and managing cash burn remain the central catalyst and risk.

In that context, the recent FDA approval of Auvelity for agitation in Alzheimer’s disease stands out as the more immediate value driver, since it expands an already marketed asset into another high need indication. Compared with SUMMIT, this approval has clearer near term relevance for revenue mix and payer discussions, and it interacts directly with existing commercialization efforts that are already reflected in Axsome’s current spending and margin profile.

Yet, despite this progress, investors should be aware that Axsome’s continued net losses and elevated SG&A could still...

Read the full narrative on Axsome Therapeutics (it's free!)

Axsome Therapeutics' narrative projects $2.5 billion revenue and $908.3 million earnings by 2029.

Uncover how Axsome Therapeutics' forecasts yield a $282.51 fair value, a 37% upside to its current price.

Exploring Other Perspectives

AXSM 1-Year Stock Price Chart
AXSM 1-Year Stock Price Chart

Some of the most optimistic analysts were modeling Axsome to reach about US$3.8 billion in revenue and US$2.4 billion in earnings by 2029, so this new SUMMIT trial could either reinforce that bullish view or highlight how dependent those forecasts are on flawless execution and late stage success in areas like Alzheimer’s agitation and narcolepsy.

Explore 7 other fair value estimates on Axsome Therapeutics - why the stock might be worth less than half the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

  • A great starting point for your Axsome Therapeutics research is our analysis highlighting 3 key rewards that could impact your investment decision.
  • Our free Axsome Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Axsome Therapeutics' overall financial health at a glance.

Curious About Other Options?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.